We found comparable frequency of cases with RPA1 variants across solid tumors (n = 22, 1.1%), CNS cancers (n = 12, 1.1%) and hematological malignancies (n = 29, 0.8%). This evidence concerns the gene RPA1 and central nervous system cancer.